Ticker

PARIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia…

BML Capital Management LLC boosted its holdings in Kezar Life Sciences, Inc. (NASDAQ: KZR) by 13.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 720,787 shares of the company's stock after buying an additional 85,604 shares during the period. Kezar Life Sciences accounts for

Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have been given an average rating of "Reduce" by the six research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a…

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).